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ABSTRACT
Population of cancer stem cells (CSCs) in breast cancer is reported to be resistant 
to chemotherapy. Furthermore, many cases of treatment failure are induced by 
the chemoresistance of CSCs in breast cancer patients. Therefore, novel strategies 
should be explored urgently to reverse drug-resistance in breast cancer stem cells 
(BCSCs). In this study, we isolated and cultured the BCSCs from the T-47D and 
SKBR3 breast cancer cell lines. We observed significant resistance to 5-fluorouracil 
in BCSCs. Mechanically, we found that expression of miR-489 was decreased in BCSCs. 
Furthermore, overexpression of miR-489 was found to increase the cytotoxicity of 
5-fluorouracil to BCSCs. XIAP, a key anti-apoptotic protein, was proved to be the 
target of miR-489. We found that enforced expression of XIAP through its recombinant 
expression vector abolished the effect of miR-489 on reversing the 5-fluorouracil 
resistance. On the contrary, embelin, a XIAP specific inhibitor, was found to sensitize 
BCSCs to 5-fluorouracil similarly with miR-489. In summary, our data demonstrate 
that introduction with miR-489 represents a novel strategy to enhance efficacy of 
5-fluorouracil-based treatment in BCSCs.
INTRODUCTION
Breast cancer represents a common malignant 
tumor, which usually leads to a high mortality rate 
in women worldwide [1]. Recently, CD44+/CD24-/low 
phenotype of breast cancer cells are reported to exhibit 
highly tumorigenic and self-renewing capability. This 
population of tumor cells are called breast cancer stem 
cells (BCSCs) [2, 3]. BCSCs initiate tumors and drive 
tumor growth and metastasis. Moreover, BCSCs are found 
to be resistant to chemotherapy. Many cases of treatment 
failure are induced by the chemoresistance of CSCs in 
breast cancer patients [4, 5, 6, 7]. Thus, it’s urgent to 
develop CSC-targeting therapies to enhances efficacy of 
chemotherapy in breast cancer.
5-Fluorouracil (5-FU) is one kind of efficient anti-
cancer drugs for treatment of various tumors including 
breast cancer in standard chemotherapy protocols. Cellular 
5-FU can be transformed into 5-oligodeoxynucleotide, 
which inhibits the activity of thymidine synthase and thus 
inhibiting DNA synthesis. Therefore, 5-FU is known to 
induce cell apoptosis in tumors including breast cancer [8, 
9, 10]. However, chemoresistance against 5-FU induced 
by long-term use of 5-FU has become a major concern 
[11]. It’s urgent to explore novel chemotherapeutic 
adjuvants which are able to decrease the 5-FU-resistance. 
MicroRNAs (miRNAs) are a new class of non-
coding RNAs that modulates the expression of targeting 
genes through binding to the 3’-untranslated region (3’-
UTR) of mRNA [12, 13]. Studies demonstrate that about 
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60% of the human genes can be potentially regulated by 
miRNAs. Therefore, they participate in various cellular 
processes such as cell proliferation, differentiation, and 
apoptosis. Moreover, dysregulation of miRNAs also 
has been reported to be involved in tumorigenesis and 
chemoresistance in tumors including breast cancer [14, 
15, 16, 17]. Thus, correcting the disorder of miRNAs 
may represent a potential strategy to enhance the 
efficacy of chemotherapy in breast cancer. Increasing 
researches demonstrate that CSCs are resistant to 5-FU 
treatment, and great efforts have been made to decrease 
the chemoresistance against 5-FU [18, 19]. In this study, 
novel strategy of introduction with miR-489 was tested to 
try to reverse the 5-FU-resistance in BCSCs.
RESULTS
BCSCs showed resistance to 5-FU treatment 
To study the sensitivity of BCSCs to 5-FU treatment, 
we firstly separated the cancer stem cell population of 
CD44+/CD24-/low phenotype [2, 3] in T-47D and SKBR3 
cell lines. As shown in Figure 1A, the proportions of 
CSCs in these breast cancer cell lines are approximately 
three to five percent. After separating and culturing these 
BCSCs, we next performed MTT assays to investigate the 
resistance of T-47D and SKBR3 CSCs to 5-FU treatment. 
As shown in Figure 1B, we found that T-47D and SKBR3 
CSCs were tolerant to 5-FU treatment compared to 
T-47D and SKBR3 non-CSCs, respectively. These results 
demonstrated the resistance of BCSCs to 5-FU treatment.
Expression of miR-489 was decreased in BCSCs
Previous studies suggested that miR-489 was a 
potential tumor suppressor in cancer cells [20]. In our 
study, we observed dysregulation of miR-489 in BCSCs. 
As shown in Figure 2A, T-47D and SKBR3 CSCs showed 
significantly lower levels of miR-489 compared to T-47D 
and SKBR3 non-CSCs, respectively. In breast cancer 
patients’ samples, we also observed significantly decrease 
of miR-489 expression in CSCs population (Figure 2B). 
We therefore needed to study the potential role of miR-
489 in BCSCs.
Overexpression of miR-489 weakened the 
resistance of BCSCs to 5-FU treatment
To correct the downregulation of miR-489 in 
BCSCs, we transfected them with miR-489 mimics. 
As shown in Figure 3A, transduction with miR-489 
mimics significantly increased the expression of miR-
489 in T-47D and SKBR3 CSCs as well as their non-
CSCs. Interestingly, we observed that overexpression of 
miR-489 significantly enhanced the cytotoxity of 5-FU 
to T-47D and SKBR3 CSCs. Specifically, compared to 
miR-C group, transfection with miR-489 decreased the 
IC50 of 5-FU by 77.5 percent to T-47D CSCs and 74.8 
percent to SKBR3 CSCs. On the other hand, effect of 
miR-489 on reducing the IC50 of 5-FU to T-47D and 
SKBR3 non-CSCs was obviously slighter than the T-47D 
and SKBR3 CSCs (Figure 3B). In addition, we found 
that 5-FU single treatment increased the proportion 
of CSC population, whereas overexpression of miR-
489 significantly suppressed the enrichment of CSC 
population induced by 5-FU (Figure 3C). Token together, 
these results indicated that CSCs were more sensitive to 
miR-489 rather than the non-CSCs. Overexpression of 
miR-489 was able to enhance the cytotoxicity of 5-FU 
to BCSCs. 
Overexpression of miR-489 enhanced the anti-
tumor effect of 5-FU in vivo
We next investigated the effect of miR-489 on 
enhancing the anti-tumor effect of 5-FU in vivo. We 
observed that miR-489 expression was significantly 
higher in the groups transduced with lentivirus-miR-489 
than groups transduced with empty lentivirus (Figure 
4A). Furthermore, tumors overexpressed miR-489 were 
more sensitive to 5-FU treatment than the control tumors 
(Figure 4B). Interestingly, we found that 5-FU single 
treatment increased the proportion of CSC population in 
control tumors, whereas the 5-FU-induced enrichment of 
CSCs was obvious slighter in miR-489-overexpressed 
tumor (Figure 4C). Together, we demonstrated that miR-
489 enhanced the anti-tumor effect of 5-FU by targeting 
CSCs in vivo.
XIAP was the target of miR-489 in BCSCs
To investigate the mechanism by which miR-
489 weakened the resistance of BCSCs to 5-FU, we 
searched for potential targets of miR-489 through online 
bioinformatics database of TargetScan, miRanda and 
PicTar. Among these potential targets, XIAP, an apoptosis 
suppressor [21], was predicted to be a target of miR-489 
because its mRNA 3’-UTR contained complementary 
sequences paired to miR-489 (Figure 5A). Besides, the 
results of western blot analysis showed that expression 
level of XIAP was upregulated in BCSCs compared to 
their corresponding non-CSCs (Figure 5B). It suggested 
the negative correlation between miR-489 and XIAP in 
breast cancer. Next, we found that overexpression of miR-
489 decreased the expression of XIAP in breast cancer 
cells, no matter whether they were treated with 5-FU in 
vitro and in vivo (Figure 5C and 5D). To confirm the effect 
of miR-489 on suppressing XIAP expression, luciferase 
reporter assays were performed in T-47D and SKBR3 
CSCs and non-CSCs. We found that overexpression of 
miR-489 decreased the luciferase activities of the pGL3 
reporter with XIAP 3’-UTR but not the empty one (Figure 
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5E). These data indicated that XIAP was the target of miR-
489 in BCSCs.
Overexpression of miR-489 decreased the 
resistance of BCSCs to 5-FU by targeting XIAP
To investigate whether the effect of miR-489 on 
reversing the 5-FU resistance in BCSCs was mediated by 
XIAP repression, we restored XIAP expression in miR-489-
overexpressed BCSCs. On the other hand, we used embelin 
which is a specific inhibitor against XIAP [22] to study 
the role of XIAP in 5-FU-based treatment in BCSCs. We 
found that XIAP restoration was able to rescue the BCSCs 
from the co-treatment with miR-489 and 5-FU. Besides, 
similarly as miR-489, embelin treatment also increased the 
sensitivity of BCSCs to 5-FU-based chemotherapy (Figure 
6A). Additionally, similarly as miR-489, embelin repressed 
the enrichment of CSC population induced by 5-FU. On 
the contrary, XIAP plasmid abolished the effect of miR-489 
on suppressing the 5-FU-induced enrichment of BCSCs 
(Figure 6B). These results indicated that miR-489 decreased 
the resistance of BCSCs to 5-FU by targeting XIAP.
MiR-489 promoted 5-FU-induced apoptosis 
in BCSCs through suppressing the function of 
XIAP
Preceding results have emphasized that decrease 
of XIAP expression was the mechanism by which miR-
489 increased the cytotoxicity of 5-FU to BCSCs. We 
next investigated the function of XIAP in BCSCs co-
treated with 5-FU and miR-489. Smac/DIABLO is 
an effective apoptotic inducer in cancer cells, which 
can be inactivated by interacting with XIAP [23]. We 
found that treatment with 5-FU induced release of 
Smac/DIABLO in BCSCs, no matter whether the miR-
489 was transfected (Figure 7A). However, because 
of the decrease of XIAP expression induced by miR-
489, interaction with XIAP and Smac/DIABLO was 
significantly inhibited in 5-FU and miR-489 co-treated 
BCSCs (Figure 7B). Similarly, amount of inactive 
caspase-3 binding to XIAP was also decreased due to 
the miR-489 overexpression (Figure 7C). As the results, 
apoptotic marker of caspase-3 and its substrate of PARP 
were dramatically activated (Figure 7D) before the 
Figure 1: BCSCs show resistance to 5-FU treatment. (A) Flow cytometry was performed to analyze the CD44+/CD24-/low phenotype 
of BCSCs in T-47D and SKBR3 cell lines. (B) T-47D and SKBR3 CSCs and non-CSCs were treated with different concentrations of 5-FU 
(0~20 μM). Forty-eight hours later, MTT assays were performed to evaluate the sensitivity of T-47D and SKBR3 CSCs and non-CSCs to 
5-FU treatment. *P < 0.05.
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apoptosis was finally appeared (Figure 7E) in BCSCs 
co-treated with miR-489 and 5-FU.
DISCUSSION
Recently, studies demonstrate that miR-489 acts as 
a tumor suppressor in several cancers. In human bladder 
cancer, miR-489 targets mRNA of JAG1, a Notch ligand, 
to suppress the proliferation and invasion of tumor 
cells [24]; In lung cancer cells, inhibition of miR-489 
upregulates the expression of N-cadherin and vimentin 
but decrease the level of E-cadherin to promote the 
epithelial mesenchymal transition (EMT) [25]. Besides 
these anti-tumor effects, miR-489 is also reported to 
increase chemosensitivity to adriamycin-resistant human 
breast cancer cells [26]. It’s clear that miR-489 inhibits 
tumorigenesis and chemoresistance in routine cancer 
cells. However, the effect of miR-489 on cancer stem 
cells (CSCs) remains unclear. CSCs, which are also called 
tumor initial cells, are responsible for tumor formation, 
recurrence and chemoresistance [27]. Here, we studied 
the association between miR-489 and chemosensitivity of 
BCSCs to 5-FU.
In the present study, we observed significant 
downregulation of miR-489 in CSC population of 
both breast cancer cell lines and patients’ specimens. 
Furthermore, functional assays showed that 
overexpression of miR-489 weakened the resistance of 
BCSCs to 5-FU and reduced the IC50 of it to BCSCs. 
In vivo tumorigenesis assays, we found that the miR-
489-overexpressed tumors were more sensitive to 5-FU 
treatment. Additionally, overexpression of miR-489 was 
able to reduce the efficacy of 5-FU to enrich the CSC 
population in BCSCs. It was probably because BCSCs 
were more sensitive to miR-489 rather than the non-CSCs. 
Taken together, our work suggested that overexpression of 
miR-489 was able to enhance the efficacy of 5-FU-based 
treatment in breast cancer by targeting BCSCs.
X-linked Inhibitor of Apoptosis Protein (XIAP), 
a member of anti-apoptotic protein family, suppresses 
apoptosis of cancer cells via interaction with apoptotic 
inducers. Functions of caspases and Smac/DIABLO which 
represent activators of apoptosis are controlled by cellular 
XIAP [28, 29]. Researches reveal that overexpression of 
XIAP contribute to resistance of cancer cells to clinical 
chemotherapeutic drugs such as 5-FU, and thus high 
expression level of XIAP is responsible for poor prognosis 
in many cancers [30, 31, 32]. As studies demonstrate that 
balance of XIAP and caspases/Smac/DIABLO determine 
the efficacy of chemotherapy [33], decreasing the level of 
XIAP is considered as an effective strategy to enhance the 
chemotherapy-induced apoptosis in cancer cells [34]. 
In the present study, we demonstrated that miR-
489 targeted XIAP in breast cancer. As expression of 
XIAP was inhibited by miR-489 in BCSCs, rescuing 
XIAP expression by using its plasmid abolished the 
effect of miR-489 on reversing the chemoresistance 
to 5-FU. On the contrary, co-treatment with embelin 
which is the specific inhibitor of XIAP also sensitized 
BCSCs to 5-FU. However, unlike the tumor suppressor 
miR-489, embelin is an exogenous herbal medicine 
with some potential toxicity. In addition, since XIAP 
inactivates caspases and Smac/DIABLO, our functional 
assays proved that overexpression of miR-489 reduced 
the interaction with XIAP and caspase-3/Smac/
DIABLO, and thus expanding the apoptotic signaling 
induced by 5-FU treatment. Token together, our work 
emphasized the importance of miR-489/XIAP axis in 
Figure 2: Expression of miR-489 was decreased in BCSCs. (A) QRT-PCR assays were performed to detect the relative expression 
of miR-489 in T-47D and SKBR3 CSCs and non-CSCs. *P < 0.05. (B) Breast cancer patients’ tissues (n = 30) were digested by collagenase 
type III. CSCs and non-CSCs in cell suspension were separated flow cytometry. Subsequently, relative expression of miR-489 in these 
CSCs and non-CSCs was detected by qRT-PCR analysis. *P < 0.05.
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chemosensitivity. One important mechanism by which 
miR-489 exerted its effect on reversing the 5-FU-
resistance was dependent on the downregulation of 
XIAP in BCSCs.
In summary, we demonstrate here that 
overexpression of miR-489 enhances efficacy of 5-FU-
based treatment in BCSCs by targeting XIAP. However, 
further efforts should be made to explore the effect of miR-
489 on other types of CSCs and other chemotherapeutic 
agents.
MATERIALS AND METHODS
Breast cancer cell lines and patients’ specimens
Human breast cancer cell lines T-47D and SKBR3 
were purchased from ATCC (American Type Culture 
Collection, Manassas,VA, USA) and cultured in DMEM 
medium (Invitrogen, Carlsbad, CA, USA) supplemented 
with 10% fetal calf serum. Cells were grown at 37 °C in 
a humidified chamber with 5% CO2. For use of surgical 
Figure 3: Overexpression of miR-489 decreased the resistance of BCSCs to 5-FU treatment. (A) Transfection with miR-
489 mimics increased the expression of miR-489 in T-47D and SKBR3 CSCs and non-CSCs. *P < 0.05. (B) Overexpression of miR-489 
enhanced the cytotoxicity of 5-FU (5 μM) to T-47D and SKBR3 CSCs and non-CSCs. *P<0.05, **P < 0.01. (C) Overexpression of miR-489 
suppressed the enrichment of CSC population induced by 5-FU (5 μM) in T-47D and SKBR3 cell lines. *P < 0.05 vs. miR-C group, #P < 
0.05 vs. 5-FU + miR-C group.
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Figure 4: Overexpression of miR-489 enhanced the anti-tumor effect of 5-FU in vivo. (A) T-47D cells were infected with 
lentivirus with miR-489 and subcutaneously injected into BALB/c nude mice (8 mice for each group). Expression of miR-489 in lentivirus-
infected tumors was detected by using qRT-PCR analysis. *P < 0.05 vs. empty lentivirus group, #P < 0.05 vs. 5-FU + empty lentivirus group. 
(B) Tumor growth in nude mice was inhibited by co-treatment with miR-489 and 5-FU (5 mg/kg 5-FU every three days) . (C) 5-FU-induced 
enrichment of CSCs was suppressed by miR-489 overexpression in tumors. *P < 0.05 vs. empty lentivirus group, #P < 0.05 vs. 5-FU + empty 
lentivirus group.
Figure 5: MiR-489 targeted XIAP in BCSCs. (A) Putative binding site of miR-489 in the XIAP 3’-UTR predicted by online 
bioinformatics database of TargetScan. (B) Upregulation of XIAP in T-47D and SKBR3 CSCs compared to their non-CSCs. (C) 
Overexpression of miR-489 in breast cancer cells decreased the expression of XIAP in vivo. (D) Overexpression of miR-489 in breast 
cancer cells decreased the expression of XIAP in vitro. (E) Transfection with miR-489 decreased the luciferase activities of the pGL3 
reporter with XIAP 3’-UTR. *P < 0.05.
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specimens derived from 30 primary breast cancer 
patients, we obtained informed consent from all of them. 
Furthermore, we obtained with the approval of the ethics 
committee of The Fifth People’s Hospital of Wuxi, The 
Medical School of Jiangnan University to use these 
specimens.
Cell sorting of CD44+/CD24-/low population in 
human breast cancer cell lines
Previous studies demonstrate that CD44+/CD24-/
low phenotype of breast cancer cells are considered as 
BCSCs [2, 3]. We therefore used CD24-FITC and CD44-
PE antibodies (BD Pharmingen, USA) to separate the 
population of BCSCs from T-47D and SKBR3 cell lines 
and patients’ tumor tissues. Briefly, single cell suspension 
of breast cancer incubated with CD24-FITC and CD44-PE 
antibodies on ice. Subsequently, the incubated cells were 
analyzed on flow cytometry. CD44+CD24−/low BCSCs were 
purified by using the fluorescent-activated cell sorting 
equipment (Beckman Coulter, USA).
Quantitative real-time polymerase chain reaction 
(qRT-PCR) for miR-489 expression
Total RNAs in T-47D and SKBR3 cell lines 
and patients’ tumor tissues were isolated by using 
TRIzol reagent (Invitrogen). Reverse transcription 
reaction for miR-489 was performed by using 
miR-489 specific stem-loop primer. The sequence 
was as follows: 5’-CTCAACTGGTGTCGTGGA 
GTCGGCAATTCAGTTGAGGCTGCCGT-3’. After 
reverse transcription of miR-489, PCR reaction was 
performed to detect the miR-489 expression by using 
SYBR® Premix Ex Taq™ II (Takara, Dalian, China) 
according to the manufacturer’s protocols. U6 snRNA 
Figure 6: MiR-489 decreased the expression of XIAP to sensitize BCSCs to 5-FU treatment. (A) After transfection with 
miR-489, miR-C and XIAP plasmid, T-47D and SKBR3 CSCs were treated with 5-FU (5 μM) and embelin (10 μM) followed by detecting 
the cell viability through MTT assays. *P < 0.05 vs. 5-FU + miR-C group, #P<0.05 vs. 5-FU + miR-489 group. (B) Unsorted T-47D and 
SKBR3 cells were transfected with miR-489, miR-C and XIAP plasmid followed by treating with 5-FU (5 μM) and embelin (10 μM). 
Population of CSCs was detected by using flow cytometry. *P < 0.05 vs. miR-C group, #P<0.05 vs. 5-FU + miR-C group, &P < 0.05 vs. 
5-FU + miR-489 group.
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was used as the internal control to normalize the relative 
expression of miR-489.
Cell transfection 
MiR-489 mimics (5ʹ-GUGACAUCACAUAU 
ACGGCAGC-3ʹ) and random RNA oligonucleotides 
(miR-C, 5ʹ-ACUGAAUACUGCGCAAACGUGC-3ʹ) 
were purchased from RiboBio Co. Ltd. (Guangzhou, 
China).XIAP open reading frame was amplified and 
then linked to the pcDNA3.1 eukaryotic expression 
vector (Invitrogen) to overexpress the gene of XIAP in 
BCSCs. For transfection,cells were cultured in 6-well 
plates overnight followed by transfecting with miR-
489 mimics (50 pmol/ml), miR-C (50 pmol/ml) and 
XIAP plasmid (2 μg/ml) by using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocols. 
After transfection, cells were collected for the following 
experiments. 
Cell viability assay
After transfection with miR-489, miR-C and 
XIAP plasmid, cells were seeded on 96-well plates 
with a concentration of 5 × 103 cell/well. Subsequently, 
cells were treated with 5-FU for forty-eight hours. 
After that, 20 μl of 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide, MTT, Sigma-Aldrich, 
USA) was added to the cells (5 mg/mL) and incubated 
at 37 °C for four hours. After incubation, MTT was 
removed, while absorbance at 570 nm was measured 
when cells were suspended in 150 μL of dimethyl 
sulfoxide (DMSO).
Luciferase reporter assay
Fragment of human XIAP mRNA 3’-UTR was 
cloned into pGL3 Luciferase Reporter Vector (Promega, 
USA). For luciferase reporter assays, cells were co-
transfected with pGL3 reporter with XIAP 3’-UTR 
and miR-489 mimics or miR-C. Forty-eight hours 
later, luciferase activities were measured by using Dual 
Luciferase Assay System (Promega) according to the 
manufacturer’s instructions.
Mitochondria removal
To obtain the protein of Smac/DIABLO in 
cytoplasm, mitochondria of BCSCs were removed by 
using Mitochondria/Cytosol Fraction Kit (BioVision, 
USA) according to the manufacturer’s instructions.
Figure 7: MiR-489 suppressed the function of XIAP to promote 5-FU-induced apoptosis in BCSCs. (A) Mitochondria in 
T-47D and SKBR3 CSCs were removed before detection of Smac/DIABLO by using western blot assays. (B) Immunoprecipitation and 
western blot assays were performed to determine the interaction with XIAP and Smac/DIABLO. (C) Immunoprecipitation and western 
blot assays were performed to determine the interaction with XIAP and caspase-3. (D) After transfection with miR-489, miR-C and XIAP 
plasmid, T-47D and SKBR3 CSCs were treated with 5-FU (5 μM) followed by detecting the cleavage of caspase-3 and PARP by using 
western blot analysis. (E) After transfection with miR-489, miR-C and XIAP plasmid, T-47D and SKBR3 CSCs were treated with 5-FU (5 
μM) followed by measuring the apoptosis using flow cytometry. *P < 0.05 vs. miR-C group, #P < 0.05 vs. 5-FU + miR-C group, &P < 0.05 
vs. 5-FU + miR-489 group.
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Immunoprecipitation and western blot
For immunoprecipitation, cytoplasm of BCSCs was 
probed with anti-XIAP (Cell Signaling Technologies, USA) 
overnight at 4°C. After that, protein A agarose beads were 
supplemented and maintained for two hours before they 
were collected by centrifugation. Subsequently, proteins 
on beads were released through boiling in sodium dodecyl 
sulfate (SDS) sample buffer. For western blot assay, proteins 
in cytoplasm of BCSCs were separated by 10% SDS-PAGE 
before they were transferred to nitrocellulose membranes. 
Subsequently, membranes were probed by anti-XIAP, anti-
Smac/DIABLO, anti-caspase-3, anti-cleaved caspase-3, anti-
cleaved PARP, anti-IgG HC and anti-GAPDH (Cell Signaling 
Technology) overnight at 4°C. Proper secondary antibodies 
were used to conjugate with the primary antibodies before the 
signals were detected by using enhanced chemilu-minescence 
detection kit (Pierce, USA).
Apoptosis analysis
Cells were transfected with miR-489, miR-C and 
XIAP plasmid before they were treated with 5 μM 5-FU. 
After treatment, cells were collected and then stained with 
Annexin-V and Propidium iodide (PI) according to the 
manufacturer’s instructions (Sigma-Aldrich, USA). Cell 
apoptosis was analyzed by using flow cytometry.
In vivo tumorigenesis assays
MiR-489 precursor sequences were amplified and 
linked to lentiviral vectors. Subsequently, lentivirus with 
miR-489 was packaged by using lentiviral packaging 
kit (Genechem Co. Ltd, Shanghai, China). For in vivo 
tumorigenesis assays, T-47D cells were infected with 1 × 
106 units of lentivirus with miR-489 (or empty lentivirus 
acted as control). Then, 5 × 106 lentivirus-infected T-47D 
cells were subcutaneously injected into female BALB/c 
nude mice (4-5-week-old). 5-FU was given through 
intraperitoneal injection every three days (5 mg/kg) after 
xenografts reached 0.5 cm in diameter. Xenograft size 
was measured every 3 days and calculated based on the 
equation of 1/2 × length × width2. All mice were sacrificed 
on day 28 days. The animal care and experimental 
protocols were approved by the Animal Care Committee 
of The Fifth People’s Hospital of Wuxi, The Medical 
School of Jiangnan University.
Statistical analysis
Data were obtained from at least three separate 
experiments and presented as mean ± standard deviation 
(SD). Statistical analysis was performed by Student’s t 
test for two groups comparison and one-way ANOVA for 
Multiple groups comparison. Comparisons were analyzed 
by using SPSS 15.0 software, and values of P < 0.05 were 
considered statistically significant.
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